Latest Articles

Publication Date
Robot-assisted versus standard laparoscopic approach of total hysterectomy for deep infiltrating endometriosis and adenomyosis (ENDORAS TRIAL): study protocol for a randomised controlled trial.

Endometriosis affects 5-10% of women during reproductive years, with a 20-30% incidence among those with infertility. Deep infiltrating endometriosis (DIE) affects 10-15% of women of childbearing age and 50% of …

Published: Nov. 28, 2025, midnight
The Financial Toxicity of Endometriosis: Unseen Costs and Policy Gaps.

Endometriosis affects 1 in 10 Canadians, yet its financial toxicity remains poorly understood. While universal healthcare covers physician and hospital services, patients face substantial out-of-pocket costs for medications, complementary therapies, …

Published: Nov. 28, 2025, midnight
m6A-Related SNPs in endometriosis and ovarian cancer: implications for chemoresistance and therapeutic targeting.

Ovarian cancer (OC) is highly lethal, largely due to late diagnosis and chemoresistance. Endometriosis (EM) increases the risk of specific OC subtypes, but the molecular connection between the two diseases …

Published: Nov. 27, 2025, midnight
The Great Masquerader: Accessory Cavitating Uterine Mass (ACUM). Evaluation, diagnosis, and surgical management.

Accessory cavitating uterine masses (ACUM) are rare, cystic uterine anomalies associated with an otherwise normal uterus and reproductive tract. They are diagnosed via a presence of a noncommunicating accessory cavity …

Published: Nov. 26, 2025, midnight
The immunotherapy era in ovarian clear cell carcinoma: current evidence and future perspective.

Ovarian clear cell carcinoma (OCCC) is a rare, aggressive epithelial ovarian cancer subtype, accounting for approximately 10% of cases and associated with a poor prognosis due to chemoresistance and unique …

Published: Nov. 26, 2025, midnight
Correction: Receptor tyrosine kinase inhibitor sunitinib as novel immunotherapy to inhibit myeloid-derived suppressor cells for treatment of endometriosis.

[This corrects the article DOI: 10.3389/fimmu.2021.641206.].

Published: Nov. 24, 2025, midnight
Venous Thromboembolism Risk Associated With Relugolix-estradiol-norethisterone Acetate Combination Therapy.

Relugolix, an oral GnRH receptor antagonist, is effective in treating uterine myomas and endometriosis. However, concerns persist regarding the venous thromboembolism (VTE) risk associated with its combination with oral estradiol …

Published: Nov. 22, 2025, midnight
Impact of Physical Rehabilitation on Endometriosis and Adenomyosis-Related Symptoms: A Systematic Review and Meta-Analysis.

Objectives: The aim of this study is to summarize recent evidence of the effectiveness of rehabilitation interventions in managing symptoms related to endometriosis and adenomyosis. Methods: The review protocol was …

Published: Nov. 21, 2025, midnight
Perineal Endometriosis Post Vaginal Stenosis Repair.

A 17 year-old 46,XX female patient with a history of urogenital reconstruction was found to have perineal endometriosis at the site of previously repaired vaginal stenosis. The patient presented in …

Published: Nov. 20, 2025, midnight
Long-Term Burden of Adolescent-Onset Endometriosis: A Case Report Highlighting Recurrent Disease and Fertility-Preserving Dilemmas.

Adolescent-onset endometriosis is increasingly recognized as a distinct clinical challenge. It often requires years to achieve a diagnosis, leading to prolonged physical and psychological distress and significantly impairing quality of …

Published: Nov. 20, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!